Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 29:7:139-47.
doi: 10.2147/CLEP.S72906. eCollection 2015.

Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy

Søren Pauli Bro  1 , Maiken Ina Siegismund Kjaersgaard  2 , Erik Thorlund Parner  2 , Merete Juul Sørensen  3 , Jørn Olsen  4 , Bodil Hammer Bech  4 , Lars Henning Pedersen  5 , Jakob Christensen  6 , Mogens Vestergaard  1
Affiliations

Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy

Søren Pauli Bro et al. Clin Epidemiol. .

Abstract

Objective: To determine if prenatal exposure to methylphenidate (MPH) or atomoxetine (ATX) increases the risk of adverse pregnancy outcomes in women with attention deficit/hyperactivity disorder (ADHD).

Materials and methods: This was a population-based cohort study of all pregnancies in Denmark from 1997 to 2008. Information on use of ADHD medication, ADHD diagnosis, and pregnancy outcomes was obtained from nationwide registers.

Results: We identified 989,932 pregnancies, in which 186 (0.02%) women used MPH/ATX and 275 (0.03%) women had been diagnosed with ADHD but who did not take MPH/ATX. Our reference pregnancies had no exposure to MPH/ATX and no ADHD diagnosis. Exposure to MPH/ATX was associated with an increased risk of spontaneous abortion (SA; ie, death of an embryo or fetus in the first 22 weeks of gestation) (adjusted relative risk [aRR] 1.55, 95% confidence interval [CI] 1.03-2.36). The risk of SA was also increased in pregnancies where the mother had ADHD but did not use MPH/ATX (aRR 1.56, 95% CI 1.11-2.20). The aRR of Apgar scores <10 was increased among exposed women (aRR 2.06, 95% CI 1.11-3.82) but not among unexposed women with ADHD (aRR 0.99, 95% CI 0.48-2.05).

Conclusion: MPH/ATX was associated with a higher risk of SA, but our study indicated that it may at least partly be explained by confounding by indication. Treatment with MPH/ATX was however associated with low Apgar scores <10, an association not found among women with ADHD who did not use MPH/ATX.

Keywords: ADHD; atomoxetine; attention deficit/hyperactivity disorder; methylphenidate; pregnancy outcomes.

PubMed Disclaimer

References

    1. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–1379. - PubMed
    1. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–718. - PubMed
    1. Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics. 2012;130(1):23–31. - PubMed
    1. Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol. 2013;69(3):589–598. - PubMed
    1. Sclar DA, Robinson LM, Bowen KA, Schmidt JM, Castillo LV, Organov AM. Attention-deficit/hyperactivity disorder among children and adolescents in the United States: trend in diagnosis and use of pharmacotherapy by gender. Clin Pediatr (Phila) 2012;51(6):584–589. - PubMed

LinkOut - more resources